Literature DB >> 667857

Hematology and clinical chemistry reference values for C57BL/6 X DBA/2 F1 mice.

S D Harrison, J A Burdeshaw, R G Crosby, A M Cusic, E P Denine.   

Abstract

We have analyzed hematology data from 504 individual male C57BL/6 X DBA/2 (hereafter called B6D2F1) mice. Clinical chemistry data from an additional 304 individual male B6D2F1 mice have also been analyzed. The mice had served as drug-diluent controls in 24 toxicological evaluations of anticancer drugs administered singly or in combination. The studies were carried out under standardized conditions during an 18-month period between July 1975 and December 1976. Test values corresponding to 9 percentiles have been selected from an ordered ranking of values for each of 18 hematologic tests and 18 clinical chemistry tests. Since 95% of the values for a given test are found between the 2.5th and 97.5th percentiles, test values corresponding to these percentiles provide reference values ("normal" values) for these mice. The other percentiles (5th, 10th, 25th, 50th, 75th, 90th, and 95th) indicate the distribution of values between the reference limits for each test. Since values for all tests do not conform to the Gaussian distribution, this nonparametric analysis provides reference values that are more accurate than might be obtained from calculation of the mean and standard deviation of a given test. The B6D2F1 mouse, commonly referred to as BDF1, has been widely used for preclinical evaluation of anticancer drugs, and these data should be useful to investigators who are conducting qualitative and quantitative toxicity evaluations in these mice.

Entities:  

Mesh:

Year:  1978        PMID: 667857

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  11 in total

1.  PPARalpha expression protects male mice from high fat-induced nonalcoholic fatty liver.

Authors:  Mohamed A Abdelmegeed; Seong-Ho Yoo; Lauren E Henderson; Frank J Gonzalez; Kimberley J Woodcroft; Byoung-Joon Song
Journal:  J Nutr       Date:  2011-02-23       Impact factor: 4.798

2.  Hematologic and histopathologic evaluation of N-(phosphonacetyl)-L-aspartate (PALA) in mice.

Authors:  S D Harrison; H D Giles; E P Denine
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

3.  Antitumor drug toxicity in tumor-free and tumor-bearing mice.

Authors:  S D Harrison; H D Giles; E P Denine
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

4.  Evaluation of antitumor drug side effects in small animals.

Authors:  W T Bradner; J E Schurig; J B Huftalen; G J Doyle
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

5.  An investigation of the mouse as a model for vincristine toxicity.

Authors:  S D Harrison
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

6.  Clinical Chemistry Reference Intervals for C57BL/6J, C57BL/6N, and C3HeB/FeJ Mice (Mus musculus).

Authors:  Gordon P Otto; Birgit Rathkolb; Manuela A Oestereicher; Christoph J Lengger; Corinna Moerth; Kateryna Micklich; Helmut Fuchs; Valérie Gailus-Durner; Eckhard Wolf; Martin Hrabě de Angelis
Journal:  J Am Assoc Lab Anim Sci       Date:  2016       Impact factor: 1.232

7.  The mouse as a model for predicting the myelosuppressive effects of anticancer drugs.

Authors:  J E Schurig; A P Florczyk; W T Bradner
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

8.  Effects of prochlorperazine on experimental nephrotoxicity.

Authors:  S D Harrison; J L Cox; R C Giles
Journal:  Cancer Chemother Pharmacol       Date:  1982-12       Impact factor: 3.333

9.  Age-Related Reference Intervals of the Main Biochemical and Hematological Parameters in C57BL/6J, 129SV/EV and C3H/HeJ Mouse Strains.

Authors:  Cristina Mazzaccara; Giuseppe Labruna; Gennaro Cito; Marzia Scarfò; Mario De Felice; Lucio Pastore; Lucia Sacchetti
Journal:  PLoS One       Date:  2008-11-20       Impact factor: 3.240

10.  Antisense suppression of the nonsense mediated decay factor Upf3b as a potential treatment for diseases caused by nonsense mutations.

Authors:  Lulu Huang; Audrey Low; Sagar S Damle; Melissa M Keenan; Steven Kuntz; Susan F Murray; Brett P Monia; Shuling Guo
Journal:  Genome Biol       Date:  2018-01-15       Impact factor: 13.583

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.